Loading treatment…
Prescription onlyFDA-approved
Zepbound®
Prescription — weekly injection pen
The FDA-approved tirzepatide product for chronic weight management — a weekly pen acting on two gut-hormone pathways, prescribed and titrated by a licensed provider.
Zepbound (tirzepatide) is FDA-approved for chronic weight management in adults with obesity, or overweight with at least one weight-related condition, alongside diet and activity.
Adding to your plan doesn't order anything and doesn't charge you — it tells the provider what you're hoping to discuss.
About 5 minutes. A licensed provider reviews your health and prescribes zepbound® only if it's right for you — there is no checkout here, and that's deliberate.
How it works
What it actually does
Zepbound is tirzepatide, which activates two receptors — GLP-1 and GIP — rather than one. The combination amplifies fullness signalling and improves how the body handles glucose, which is why its trial results lead the class. As the manufacturer's finished pen, dosing is verified under FDA oversight.
See the full mechanism, step by stepThe evidence
What the trials actually found
Published results, with what they were measured against. A number without a comparator isn't evidence — it's advertising.
20.9% mean body-weight reduction
vs 3.1% on placebo
Over 72 weeks at the 15mg weekly dose, alongside lifestyle intervention, in adults with obesity without diabetes.
Jastreboff et al., SURMOUNT-1 trial, New England Journal of Medicine, 2022
Trial averages describe a study population, not a prediction for you. Your provider will be direct about what is realistic given your history — and results depend on continuing treatment.
A provider may consider it if
- You want the strongest trial-evidence in the class, as the FDA-approved product
- You're ready for stepwise dose increases with provider check-ins
- Your insurance may cover it — worth checking before paying cash
It won't be prescribed if
- Anyone with a personal or family history of medullary thyroid carcinoma, or MEN 2 syndrome — this is a hard stop
- Pregnancy, trying to become pregnant, or breastfeeding
- A history of pancreatitis, without careful provider review
- Type 1 diabetes, gastroparesis, or an active eating disorder without in-person care
These are the same checks the visit runs. If one applies, the visit will tell you plainly rather than take your money.
What to expect
Realistically, month by month
Weeks 1–4
Treatment starts at 2.5mg weekly — an adaptation dose, not the treatment dose.
Months 1–6
The dose steps up gradually (to 5, 10, up to 15mg weekly) as tolerated, with provider review at each stage.
Ongoing
Managed as an ongoing condition, with the dose revisited at check-ins rather than set once and forgotten.
Safety, stated up front
Side effects, before you decide
Nausea, diarrhoea, vomiting and constipation are the common ones, typically around dose increases. Serious but uncommon risks include pancreatitis and gallbladder disease; the class boxed warning covers thyroid C-cell tumors seen in rodents. Full prescribing information comes with every prescription.
- FDA prescribing information: Zepbound (tirzepatide) injection
- Boxed warning: thyroid C-cell tumors in rodents; contraindicated with personal or family history of MTC or MEN 2
Complete safety information is provided during your visit and with every prescription. This page is a summary, not a substitute for your provider's advice.
Questions
Asked honestly, answered honestly
How is this different from Wegovy?
Different molecule, overlapping mechanism: Zepbound acts on two receptors (GLP-1 and GIP) where Wegovy acts on one. Head-to-head trial data (SURMOUNT-5) favored tirzepatide on average weight loss. Which is right for you is your provider's call, not a marketing page's.
Will I definitely be prescribed this?
No — a licensed provider reviews your health history and prescribes only if it's appropriate and safe for you. If it isn't, we'll tell you why, and the medication portion of any payment is refunded.
See whether zepbound® is right for you
Five minutes of questions, reviewed by a licensed provider. Treatment only if it's appropriate — and a straight answer either way.